Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

PHASE2CompletedINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

June 6, 2020

Primary Completion Date

November 5, 2020

Study Completion Date

November 5, 2020

Conditions
Ocular HypertensionPrimary Open Angle Glaucoma
Interventions
DRUG

Latanoprost ophthalmic solution

Latanoprost opthalmic solution to be dosed once daily

DRUG

AKB-9778 4%

Razuprotafib opthalmic solution

DRUG

Placebo

placebo for razuprotafib opthalmic solution

Trial Locations (21)

14618

North Valley Eye Medical Group, Rochester

16066

Scott & Christie and Assoc, Cranberry Township

18704

Eye Care Specialists, Kingston

27101

James D. Branch, MD Ophthalmology, Winston-Salem

28210

Charlotte Eye, Ear, Nose & Throat Assoc. (CEENTA), Charlotte

30076

Coastal Research Associates, Roswell

30260

Clayton Eye Clinical Research, LLC, Morrow

33773

Shettle Eye Research, Largo

37205

Advancing Vision Research, Nashville

38119

Total Eye Care, Memphis

44115

Abrams Eye Center, Cleveland

45242

Apex Eye, Cincinnati

63128

Tekwani Vision Center, St Louis

66204

Heart of America Eye Care, P.A., Shawnee Mission

66762

Kannarr Eye Care, Pittsburg

74104

Mark J. Weiss, MD, Inc., Tulsa

78731

Texan Eye / Keystone Research, Austin

90301

United Medical Research Institute, Inglewood

91345

North Valley Eye Medical Group, Mission Hills

92663

Eye Research Foundation, Newport Beach

94954

North Bay Eye Associates, Petaluma

Sponsors
All Listed Sponsors
lead

EyePoint Pharmaceuticals, Inc.

INDUSTRY